These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6180584)

  • 21. The plasminogen activator and esterase activities of the two forms of urokinase.
    Ong EB; Soberano ME; Johnson AJ; Dharmgrongartama ED
    Thromb Res; 1981 Nov; 24(3):223-32. PubMed ID: 7038974
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of urokinase on growth and metastases of rabbit V2 carcinoma.
    Kodama Y; Tanaka K
    Gan; 1978 Feb; 69(1):9-18. PubMed ID: 640328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A role of fibrin deposits in the development of rabbit Masugi nephritis and effect of urokinase on the experimental glomerulonephritis (author's transl)].
    Akiba T; Tanaka K
    Nihon Jinzo Gakkai Shi; 1982 Feb; 24(2):125-38. PubMed ID: 7047822
    [No Abstract]   [Full Text] [Related]  

  • 24. The inhibitory effect of plasma inhibitor on plasmin activated with streptokinase or urokinase.
    Sumi H; Takada Y; Takada A
    Nihon Seirigaku Zasshi; 1977; 39(5):112-4. PubMed ID: 72149
    [No Abstract]   [Full Text] [Related]  

  • 25. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
    Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urokinase immobilized on medical polymeric materials: fundamental and clinical studies.
    Ohshiro T; Kosaki G
    Artif Organs; 1980 Feb; 4(1):58-4. PubMed ID: 6989347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Enhanced cell killing by thio-TEPA and urokinase (author's transl)].
    Taya T
    Nihon Hinyokika Gakkai Zasshi; 1979 Jan; 70(1):15-27. PubMed ID: 107356
    [No Abstract]   [Full Text] [Related]  

  • 28. Vasodilation due to urokinase in the canine femoral circulation.
    Gurll NJ; Zinner MJ; Callahan W; Reynolds DG
    J Pharmacol Exp Ther; 1977 Jun; 201(3):731-7. PubMed ID: 864605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 30. Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins.
    Toki N; Sumi H; Sasaki K; Boreisha I; Robbins KC
    J Clin Invest; 1985 Apr; 75(4):1212-22. PubMed ID: 3921568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Water-soluble modified derivatives of urokinase: fibrinolytic activity and other properties].
    Maksimenko AV; Torchilin VP
    Vopr Med Khim; 1985; 31(4):12-20. PubMed ID: 4049780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immobilization of plasminogen activator, urokinase, on nylon.
    Sugitachi A; Takagi K; Imaoka S; Kosaki G
    Thromb Haemost; 1978 Apr; 39(2):426-36. PubMed ID: 580991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Inactivation and stabilization of urokinase fibrinolytic activity in vitro].
    Aĭsina RB; Mukhametova LI; Sazonova IIu; Varfolomeev SD
    Bioorg Khim; 1998 Jul; 24(7):544-8. PubMed ID: 9749317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
    Bode C; Eberle T; Runge M; Haber E; Kübler W
    Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
    [No Abstract]   [Full Text] [Related]  

  • 35. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
    Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
    Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
    [No Abstract]   [Full Text] [Related]  

  • 36. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
    Singh K; Vézina C
    J Med; 1974; 5(6):297-302. PubMed ID: 4528600
    [No Abstract]   [Full Text] [Related]  

  • 37. [In vitro measurement of fibrinolysis by urokinase].
    Senf L
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):819-21. PubMed ID: 6176506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Threshold phenomena in blood fibrinolysis.
    Matsuo O; Mihara H
    Thromb Res; 1977 May; 10(5):753-8. PubMed ID: 882961
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of drugs and parenteral solutions on vascular fibrinolytic activity.
    Johnston WE; Silver D
    Surgery; 1975 Aug; 78(2):202-10. PubMed ID: 1154264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
    Thorsen S
    Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.